GCell announced that its first-in-class allogeneic umbilical cord blood-derived CD5-targeting CAR-NK cell therapy, 'GCC2005,' was introduced through an oral presentation at the 17th T Cell Lymphoma Forum (TCLF) held in San Diego, USA, on January 30 (local time).


The TCLF is a specialized conference where global experts in the field of T-cell lymphoma gather to discuss the latest research findings, as well as diagnostic and therapeutic strategies. Unlike general hematology conferences, this forum is characterized by in-depth discussions among specialists focused exclusively on this disease area.

Professor Wonseok Kim of the Department of Hematology and Oncology at Samsung Medical Center is delivering consecutive oral presentations on the next-generation CD5 CAR-NK therapy at the American T-Cell Lymphoma Specialized Conference. GCell

Professor Wonseok Kim of the Department of Hematology and Oncology at Samsung Medical Center is delivering consecutive oral presentations on the next-generation CD5 CAR-NK therapy at the American T-Cell Lymphoma Specialized Conference. GCell

View original image

Following its oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting last year, GCC2005 was again presented at the TCLF, further demonstrating its clinical value and technological competitiveness as a treatment for relapsed and refractory T-cell lymphoma, as recognized by the global academic community.


This presentation was delivered by Professor Wonseok Kim of the Department of Hematology and Oncology at Samsung Medical Center, during the session titled 'The Role of Adoptive Cellular and Immunotherapies for PTCL.' He presented on 'Development of CD5 CAR-NK Cell Therapy in PTCL.'


The presentation detailed the development history of GCC2005, from its initial research and development phase to its current clinical stage. In particular, the rationale for selecting the optimal CAR structure was shared, along with in vitro and in vivo characterization data, demonstrating GCell's scientific research capabilities. Additionally, the presentation highlighted experimental results showing a significant reduction in the risks of 'fratricide' and 'T cell aplasia,' which are chronic limitations of existing autologous CAR-T therapies, garnering attention from global stakeholders.


The presentation also included interim results from a domestic phase 1 clinical trial (NCT06699771) previously released at ASH. In the interim analysis of phase 1a, an initial safety assessment was conducted on nine patients with CD5-positive relapsed or refractory NK/T-cell lymphoma. No dose-limiting toxicity (DLT) or serious adverse events were observed, and infection issues frequently reported with competing CD5 CAR-T therapies were also absent.


In terms of efficacy, meaningful results were observed. Among eight patients evaluable for tumor response, the objective response rate (ORR) was 62.5%, with three patients achieving complete remission (CR) and two achieving partial remission (PR). Considering that the typical response rate for conventional anticancer drugs is below 30%, these numbers are encouraging.


Notably, there was a case where complete remission was achieved after just a single dose, further supporting the antitumor potential of GCC2005. The response rate tended to improve with increasing dose, and even among some patients with disease progression, a reduction in target lesions was observed.


Additionally, a case involving a patient with angioimmunoblastic T-cell lymphoma (AITL) was shared. This patient, despite having failed three prior treatments and receiving only the lowest dose in the first cohort, maintained complete remission for six months after treatment, and is currently under follow-up at the nine-month mark.


GCell is currently conducting a dose-escalation study for the high-dose cohort of GCC2005 and plans to expand development to a domestic phase 1b trial (dose expansion) and a global phase 2 trial in the future.



Seongyong Won, CEO of GCell, stated, "It is very meaningful to share the achievements of GCC2005 at the TCLF, where leading global scholars gather. Based on the high expectations confirmed at both ASH and TCLF, we will expedite the remaining clinical procedures and solidify global partnership discussions to provide innovative treatment options to patients worldwide."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing